CoChat

Association between first‐line monotherapy with sulphonylurea versus metformin and risk of all‐cause mortality and cardiovascular events: a retrospective, observational study

Morgan, C. Ll., Mukherjee, J., Jenkins‐Jones, S., Holden, S. E., Currie, C. J. · 2014 · Diabetes, Obesity and Metabolism
Cited by 71

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aims: To evaluate the risk of all‐cause mortality and major adverse cardiovascular events ( MACE ) for patients exposed to first‐line monotherapy with sulphonylurea or metformin. Methods: Data were from the Clinical Practice Research Datalink ( CPRD ). Patients with type 2 diabetes were selected if initiated with metformin or sulphonylurea monotherapy as their first‐line glucose‐lowering regimen 2000–2012. The primary endpoint was all‐cause mortality; the secondary endpoint was MACE (myocardial infarction or stroke). Times to endpoints were compared using Cox proportional hazards models. Additional analyses were performed on subsets matched directly on key characteristics and by propensity score. Results: In the main analysis, 76 811 patients were prescribed metformin monotherapy (mean follow‐up 2.9 years) and 15 687 sulphonylurea monotherapy (mean follow‐up 3.1 years). A total of 2604 patients were included in each arm of the directly matched cohorts and 8836 in the propensity‐matched. With respect to all‐cause mortality, using all three analytical approaches the hazard ratio ( HR ) was significantly increased for sulphonylurea compared with metformin: adjusted HR = 1.580 (95% CI 1.483–1.684) for the main analysis, 1.902 (1.733–2.088) for those matched on propensity score, and 1.272 (1.021–1.584) for the directly matched cohort analysis. For MACE , the respective HRs were 1.196 (1.090–1.313), 1.202 (1.001–1.442) and 0.814 (0.578–1.148), respectively. Conclusions: All‐cause mortality was significantly increased in patients prescribed sulphonylurea compared with metformin monotherapy. Whilst residual confounding and confounding by indication may remain, this study indicates that first‐line treatment with sulphonylurea monotherapy should be reconsidered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12302

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Morgan, C. L., Mukherjee, J., Jenkins‐Jones, S., Holden, S. E., & Currie, C. J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2014-05-08
Volume
16
Issue
10
Pages
957-962
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2020388702
Cited by
71
References
9
FWCI
10.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.